Vane J R, Botting R M. New insights into the mode of action of anti-inflammatory drugs[J].Inflamm Res,1995, 44:1-10.
[2]
Jaradat N. Phytochemical profile and in vitro antioxidant, antimicrobial, vital physiological enzymes inhibitory and cytotoxic effects of artemisia jordanica leaves essential oil from palestine[J]. Molecules, 2021, 26(9): 2831.
[3]
Berbecka M, Forma A, Baj J, et al. A systematic review of the cyclooxygenase-2 (COX-2) expression in rectal cancer patients treated with preoperative radiotherapy or radiochemotherapy[J]. J Clin Med, 2021, 10(19): 4443.
Ishi Y, Harada T, Kameda H, et al. Variations and natural history of primary intraparenchymal lesions associated with neurofibromatosis type 2[J]. Neuroradiology, 2022, 64(2):393-396.
Guerrant W, Kota S, Troutman S, et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis[J]. Cancer Res, 2016,76(12):3507-3519.
[10]
Birzu C, French P J, Caccese M, et al. Recurrent glioblastoma: from molecular landscape to new treatment perspectives[J]. Cancers, 2021, 13(1):47.
Shahcheraghi S H, Tchokonte-Nana V, Lotfi M, et al. Wnt/beta-catenin and PI3K/Akt/mTOR signaling pathways in glioblastoma: two main targets for drug design: a review[J]. Curr Pharm Design, 2020, 26(15):1729-1741.
[13]
Liu X, Gao Q, Zhao N, et al. Sohlh1 suppresses glioblastoma cell proliferation, migration and invasion by inhibition of Wnt/β-catenin signaling[J]. Mol Carcin, 2018,57(4):494-502.
[14]
Majchrzak C A, Misiorek J O, Kruhlenia N, et al. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β- catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells[J]. BMC Cancer, 2021, 21(493):1-18.
[15]
Alqahtani A M, Chidambaram K, Pino-Figueroa A, et al. Curcumin-celecoxib: a synergistic and rationale combination chemotherapy for breast cancer[J]. Eur Rev Med Pharmaco Sci, 2021, 25(4): 1916-1927.
[16]
Thijs R D, Surges R, O'Brien T J, et al. Epilepsy in adults[J]. The Lancet, 2019, 393(10172): 689-701.
[17]
Leguia M G, Andrzejak R G, Rummel C, et al. Seizure cycles in focal epilepsy[J]. JAMA Neurol,2021,78(4):454-463.
Sanz P, Garcia-Gimeno M A. Reactive glia inflammatory signaling pathways and epilepsy[J]. Int J Mol Sci, 2020, 21(11):4096.
[20]
Citraro R, Leo A, Marra R, et al. Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats[J]. Brain Res Bull, 2015, 113:1-7.
[21]
Katyal J, Kumar H, Gupta Y K. Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment[J]. Epilepsy Behav, 2015, 44:98-103.
[22]
Alsaegh H, Eweis H, Kamel F, et al. Celecoxib decrease seizures susceptibility in a rat model of inflammation by inhibiting HMGB1 translocation[J]. Pharmaceuticals, 2021, 14(4):380.
[23]
Polascheck N, Bankstahl M, LScher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy[J]. Exp Neurol, 2010, 224(1):219-233.
[24]
Chan P C, Liao M T, Hsieh P S. The dualistic effect of COX-2-mediated signaling in obesity and insulin resistance[J]. Int J Mol Sci, 2019, 20(13):3115.
[25]
Chan P C, Wu T N, Chen Y C, et al. Targeted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance[J]. Clin Sci, 2018, 132(14):1581-1596.
[26]
Rasha F, Ramalingam L, Gollahon L, et al. Mechanisms linking the renin-angiotensin system, obesity, and breast cancer[J]. Endocr Cancer, 2019, 26(12): 653-672.
[27]
Ekor M, Owusu P E, Obese E, et al. Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia[J]. PloS One, 2021, 16(8): e0247735.
[28]
Lula J, Paula A D, Guimaraes A, et al. Cox enzyme inhibitor, celecoxib, reduces steatosis and liver lipogenesis in high-fat fed mice[J]. Curr Enzyme Inhibit, 2018, 14(2):114-119.
[29]
Lebedeva E S, Kuzubova N N, Titova O N, et al. Effect of cyclooxygenase-2 inhibition on lung inflammation and hypoxia-inducible factor-1 signalling in COPD model[J].Eur Respir J,2017, 50:3926.
[30]
Azmoonfar R, Amini P, Saffar H, et al. Celecoxib a selective COX-2 inhibitor mitigates fibrosis but not pneumonitis following lung irradiation: a histopathological study[J]. Curr Drug Ther, 2020, 15(4):351-357.
[31]
Jin H. Imrecoxib inhibits paraquat-induced pulmonary fibrosis through the NF-κB/snail signaling pathway[J]. Comput Math Method M, 2020, 2020: 1-9.
[32]
Majd M, Saunders E, Engeland C G. Inflammation and the dimensions of depression: a review[J]. Front Neuroendocrinol, 2019, 56:100800.
[33]
Leonard B E. Inflammation and depression: a causal or coincidental link to the pathophysiology?[J]. Acta Neuropsychiatr, 2017, 30(1):1-16.
[34]
Dooley L N, Kuhlman K R, Robles T F, et al. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation[J]. Neurosci Biobehav Res, 2018, 94: 219-237.
[35]
Felger J C. Role of inflammation in depression and treatment implications[M].Antidepressants Springer:Cham, 2018: 255-286.,
Faridhosseini F, Sadeghi R, Farid L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials[J]. Hum Psychopharm Clin, 2014, 29(3):216-223.
[38]
Kurhe Y, Mahesh R, Gupta D. Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests[J]. Neurochem Res, 2014, 39(7):1395-1402.
[39]
Na K S, Lee K J, Lee J S, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis[J]. Prog Neuro Psychoph, 2014, 48:79-85.
Huang Z, Ma X, Jia X, et al. Prevention of severe acute pancreatitis with cyclooxygenase-2 inhibitors: a randomized controlled clinical trial[J]. Am J Gastroenterol, 2020, 115(3): 473.
Wallace J L, Soldato P D. The therapeutic potential of NO-NSAIDs[J]. Fund Clin Pharmacol, 2003, 17(1): 11-20.
[46]
Bakr R B, Abdelall E, Abdellatif K,et al. Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents[J]. Curr Top Med Chem, 2017, 17(8): 941-955.
[47]
Bechmann N, Kniess T, Köckerling M, et al. Novel (pyrazolyl) benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors[J]. Bioorg Med Chem Lett,2015, 25(16): 3295-3300.
[48]
Consalvi S, Poce G, Ragno R, et al. A series of COX-2 inhibitors endowed with NO-releasing properties: synthesis, biological evaluation, and docking analysis[J]. Chem Med Chem, 2016, 11(16): 1804-1811.
[49]
Almansa C, Merce R, Tesson N, et al. Co-crystal of tramadol hydrochloride-celecoxib (CTC): a novel API-API co-crystal for the treatment of pain[J]. Cryst Growth Des, 2017, 17(4): 1884-1892.
2022, Vol. 33 
